- Home
- AVBC vs LRMR Comparison
AVBC vs LRMR Comparison
Compare AVBC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBC
- LRMR
- Stock Information
- Founded
- AVBC 1869
- LRMR N/A
- Country
- AVBC United States
- LRMR United States
- Employees
- AVBC N/A
- LRMR N/A
- Industry
- AVBC
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- AVBC
- LRMR Health Care
- Exchange
- AVBC Nasdaq
- LRMR Nasdaq
- Market Cap
- AVBC 316.2M
- LRMR 360.3M
- IPO Year
- AVBC N/A
- LRMR N/A
- Fundamental
- Price
- AVBC $14.77
- LRMR $4.32
- Analyst Decision
- AVBC Strong Buy
- LRMR Strong Buy
- Analyst Count
- AVBC 1
- LRMR 7
- Target Price
- AVBC $18.00
- LRMR $16.71
- AVG Volume (30 Days)
- AVBC 53.9K
- LRMR 4.5M
- Earning Date
- AVBC 10-23-2025
- LRMR 11-14-2025
- Dividend Yield
- AVBC N/A
- LRMR N/A
- EPS Growth
- AVBC N/A
- LRMR N/A
- EPS
- AVBC N/A
- LRMR N/A
- Revenue
- AVBC $79,463,000.00
- LRMR N/A
- Revenue This Year
- AVBC N/A
- LRMR N/A
- Revenue Next Year
- AVBC N/A
- LRMR N/A
- P/E Ratio
- AVBC N/A
- LRMR N/A
- Revenue Growth
- AVBC N/A
- LRMR N/A
- 52 Week Low
- AVBC $14.00
- LRMR $1.61
- 52 Week High
- AVBC $15.99
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- AVBC N/A
- LRMR 51.58
- Support Level
- AVBC N/A
- LRMR $3.87
- Resistance Level
- AVBC N/A
- LRMR $4.33
- Average True Range (ATR)
- AVBC 0.00
- LRMR 0.30
- MACD
- AVBC 0.00
- LRMR -0.03
- Stochastic Oscillator
- AVBC 0.00
- LRMR 40.44
About AVBC Avidia Bancorp Inc.
Avidia Bancorp Inc business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial and industrial loans, one-to four-family residential mortgage loans, and commercial real estate loans.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.